Micheal O. Lawal
“Creating material for cannabis and holistic well-being involves more than just stringing together words. It requires infusing each sentence with sincere concern, blending genuine sincerity with pertinence, and transforming complex health ideas into accessible knowledge for everyone.”
About
Micheal is a writer with a passion for health and cannabis. Before he began writing about cannabis almost three years ago, Micheal ventured into health administration, gaining valuable insights into patient care, healthcare systems, and health-related topics. His love for patients’ well-being was further strengthened with 18 months of experience writing about the complexities of alcohol addiction and its recovery. He has since been dedicated to exploring the multifaceted relationship between cannabis and well-being and the grey line between laws and usage.
Outside of health, Micheal, a football fanatic, writes about various subjects across several industries, helping businesses create value and sell their brands.
Articles
Next Year, SXSW 2027 May Spotlight Cannabis and Psychedelics
South by Southwest just proved that cannabis at SXSW 2027 is no longer a niche conversation. Attendees can vote on seven panels that mention cannabis
Inside the Hemp Cannabinoid Ban 2026 and What It Means for HHC Consumers
Federal regulators and hemp companies are fighting over the fate of HHC, delta-8, and other synthetic cannabinoids sold nationwide. The DEA already assigned HHC its
VA Announces Psilocybin Therapy Trial for Veterans With Depression and PTSD
The Department of Veterans Affairs just opened a new clinical trial testing whether psilocybin can help veterans with treatment-resistant depression, including those who also live
Hemp THC Ban 2026: What the New Attorneys General Letter Means for You
A coalition of 35 state attorneys general just told Congress to leave the hemp THC ban 2026 alone. Their letter, published this week, urges lawmakers
Does Marijuana Legalization Increase Teen Use? Federal Studies Say No
A new federal report puts a persistent fear to rest. SAMHSA’s newly published 2025 National Survey on Drug Use and Health answers one of cannabis
Eli Lilly Just Spent $2.8 Billion on a Psychedelic Drug — Here’s Why That’s a Huge Deal
One of the largest drug companies in the world just made a $2.8 billion bet on a substance most people associate with underground rituals, not